Orchestra BioMed opened lower at $5.99, compared with its previous close of $6.01. In the last trading session, the stock traded between $5.70 and $6.18. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Orchestra BioMed is now worth
$ 53.43
Resulting in a loss of
$ 46.57 (46.57%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.14 (+2.25%)
Day High
$6.18
Day Low
$5.70
Day Open
$5.99
Prev Close
$6.01
Volume
4,82,861
1W Return
2.26%
1M Return
3.80%
3M Return
39.95%
6M Return
57.16%
1Y Return
49.88%
Fundamentals
Market Cap ($ Mn)
484
PE Ratio
-
PB Ratio
16.13
PEG Ratio
-
ROE
-178.75%
ROCE
-82.73%
EPS (TTM)
$-0.40
Investment Returns
1 Week
2.26%
1 Month
3.80%
3 Months
39.95%
6 Months
57.16%
9 Months
51.35%
Financials
Quarterly
All values in $ Mn
0.3
Dec 24
0.9
Mar 25
0.8
Jun 25
0.9
Sep 25
30.9
Dec 25
0.1
Jun 26
Updates
11Nov
Orchestra BioMed Q3 Results: Loss narrows 25%, sales drop 89%
Loss per share narrowed to $(0.30), beating estimates by 25%. Quarterly sales dropped 89% to $91.000 thousand. Revenue missed analyst consensus by 14.15%. Prior year sales stood at $861.000 thousand.
2 days ago
3Sep
Orchestra BioMed grants 133,000 stock options to seven new hires
Orchestra BioMed granted stock options to buy 133,000 shares to seven new hires. Awards vest over four years under the 2025 New Hire Inducement Plan. Disclosure made pursuant to Nasdaq Listing Rule 5635(c)(4). Company continues pivotal trials for AVIM Therapy and Virtue SAB.
2mo ago
27Aug
Orchestra BioMed CEO to present at H.C. Wainwright conference
Orchestra BioMed CEO David Hochman to present at H.C. Wainwright conference on Sept. 16, 2026. Hochman will also host one-on-one investor meetings during the event. AVIM Therapy holds FDA Breakthrough Designation and targets 7.7 million U.S. patients. Virtue SAB holds FDA Breakthrough Designation for three atherosclerotic artery disease indications. Company collaborates with Medtronic on development and commercialization of AVIM Therapy.
2mo ago
11Aug
Orchestra BioMed reports $24.1M Q2 loss, secures $35M capital
Orchestra BioMed Holdings reported a widened Q2 2026 net loss of $24.1 million amid an 89% revenue drop to $88,000. Rising R&D expenses drove the loss, but a $35 million capital injection from Medtronic and Ligand extended the cash runway to Q4 2027, supporting pivotal trials for AVIM Therapy and Virtue SAB.
3mo ago
29Jun
Orchestra BioMed joins Russell 3000 and Russell 2000 indexes
Orchestra BioMed Holdings, Inc. was added to the Russell 3000 and Russell 2000 indexes effective June 26, 2026, following the annual reconstitution based on market capitalization rankings. The company focuses on biomedical innovations like AVIM Therapy and Virtue SAB, both in pivotal trials and holding FDA Breakthrough Device Designations.
